Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Kumar, Sachin ^a   Guleria, Randeep ^a   Singh, Vikas ^a   Bharti, Alok C ^b   Mohan, Anant ^a   Das, Bhudev C ^c  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE OF CYTOLOGY AND PREVENTIVE ONCOLOGY   (India)

^c UNIVERSITY OF DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

PLATINUM DERIVATIVE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; ENDOTHELIAL CELL GROWTH FACTOR; TUMOR MARKER;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; KINETICS; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIMARY HEALTH CARE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 73149124713     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-421     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Brambilla C, Fievet F, Jeanmart M, de Fraipont F, Lantuejoul S, Frappat V, Ferretti G, Brichon PY, Moro-Sibilot D. Early detection of lung cancer: role of biomarkers. Eur Respir J Suppl 2003, 39:36s-44s. 10.1183/09031936.02.00062002, 12572700.
3. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Eng J Med 2004, 350:379-392.
4. Holdenrieder S, Stieber P, v Pawel J, Raith H, Nagel D, Feldmann K, Seidel D. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004, 10:5981-5987. 10.1158/1078-0432.CCR-04-0625, 15447981.
5. Holdenrieder S, Stieber P, v Pawel J, Raith H, Nagel D, Feldmann K, Seidel D. Early and specific prediction of the therapeutic efficacy in lung cancer by nucleosomal DNA and cytokeratin 19 fragments. Ann NY Acad Sci 2006, 1075:244-257. 10.1196/annals.1368.033, 17108218.
6. Vollmer RT, Govindan R, Graziano SL, Gamble G, Garst J, Kelley MJ, Christenson RH. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. Clin Cancer Res 2003, 9:1728-1733.
7. Stieber P, Hasholzner U, Bodenmüller H, Nagel D, Sunder-Plassmann L, Dienemann H, Meier W, Fateh-Moghadam A. CYFRA 21-1: A new marker in lung cancer. Cancer 1993, 72:707-213. 10.1002/1097-0142(19930801)72:3<707::AID-CNCR2820720313>3.0.CO;2-X, 7687515.
8. Ebert W, Muley T. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy. Anticancer Res 1999, 19:2669-2672.
9. Molina R, Filella X, Augé JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Viñolas N, Marquez A, Barreiro E, Borras J, Viladiu P. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003, 24:209-218. 10.1159/000074432, 14654716.
10. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997, 111:1710-1717. 10.1378/chest.111.6.1710, 9187198.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
12. Kido Y. Vascular endothelial growth factor (VEGF) serum concentration changes during chemotherapy in patients with lung cancer. Kurume Med J 2001, 48:43-47.
13. Colakogullari M, Ulukaya E, Yilmaztepe A, Ocakoglu G, Yilmaz M, Karadag M, Tokullugil A. Higher serum nitrate levels are associated with poor survival in lung cancer patients. Clin Biochem 2006, 39:898-903. 10.1016/j.clinbiochem.2006.06.008, 16919616.
14. Mihaylova Z, Ludovini V, Gregorg V, Floriani I, Pistola L, Toffaneti F, Ferraldeschi M, Spreafico A, Ceresoli GL, Bellet M, Darwish S, Tonato M, Raynov J. Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients. J BUON 2007, 12:105-111.
15. Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F, Choy H. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 2009, 15:2158-2165. 10.1158/1078-0432.CCR-08-0629, 19276291.
16. Yoshimoto A, Kasahara K, Nishio M, Hourai T, Sone T, Kimura H, Fujimura M, Nakao S. Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer. Jpn J Clin Oncol 2005, 35:233-238. 10.1093/jjco/hyi074, 15886272.
17. Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, Lo Vullo S, Mansueto G, Bonginelli P, Gattuso D, Gion M. The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates. Cancer J 2005, 11:209-216. 10.1097/00130404-200505000-00007, 16053664.
18. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest 2006, 24:492-496. 10.1080/07357900600814771, 16939957.
19. Ustuner Z, Saip P, Yasasever V, Vural B, Yazar A, Bal C, Ozturk B, Ozbek U, Topuz E. Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients. Med Oncol 2008, 25:394-399. 10.1007/s12032-008-9052-4, 18317954.
20. Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, Herbst RS, Johnson BE, Heymach JV. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009, 15:3600-3609. 10.1158/1078-0432.CCR-08-2568, 19447868.
21. Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, Nishio K, Saijo N, Fukuoka M. A randomized, double-blind, phase IIa dose-finding study of vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2008, 3:386-393. 10.1097/JTO.0b013e318168d228, 18379357.
22. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008, 14:1407-1412. 10.1158/1078-0432.CCR-07-1154, 18316562.
23. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Serum vascular endothelial growth factor (VEGF) and Bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest 2006, 24:576-580. 10.1080/07357900600894781, 16982461.
24. Laack E, Köhler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, Niestroy A, Dahlmann N, Peters A, Berger J, Fiedler W, Hossfeld DK. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small cell lung cancer. Ann Oncol 2002, 13:1550-1557. 10.1093/annonc/mdf270, 12377642.
25. Chakra M, Pujol JL, Lamy PJ, Bozonnat MC, Quantin X, Jacot W, Daurès JP. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. J Thorac Oncol 2008, 3:1119-1126. 10.1097/JTO.0b013e318187464e, 18827607.
26. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 2005, 23:193-200. 10.1081/CNV-200055949, 15945504.
27. Shimanuki Y, Takahashi K, Cui R, Hori S, Takahashi F, Miyamoto H, Fukurchi Y. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 2005, 183:29-42. 10.1007/s00408-004-2521-4, 15793665.
28. Park JH, Choi H, Kim YB, Kim YS, Sheen SS, Choi JH, Lee HL, Lee KS, Chung WY, Lee S, Park KJ, Hwang SC, Lee KB, Park KJ. Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer. Lung Cancer 2009, 66:359-364. 10.1016/j.lungcan.2009.03.002, 19339077.
29. Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E, Chechlinska M, Steffen J. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor. Oncology 2006, 70:115-125. 10.1159/000093002, 16645324.